Sobi Announces CHMP's Positive Opinion For Aspaveli
I'm PortAI, I can summarize articles.
Sobi announced that the European Medicines Agency's CHMP has given a positive opinion for the marketing authorisation of Aspaveli (pegcetacoplan) for treating C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. The decision is based on Phase 3 VALIANT study results, with European Commission approval expected in Q1 2026. Sobi and Apellis Pharmaceuticals have global co-development rights for the drug.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments